Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dong-A ST Co. Ltd.

en.donga-st.com

Latest From Dong-A ST Co. Ltd.

Start-Up Quarterly Statistics: Financings Continue Quarterly Declines Despite Big Venture Deals And IPOs

A review of biopharma start-up dealmaking and financing activity from July through September 2019, based on data from Strategic Transactions. Fundraising activity fell 23% from the second to the third quarter, but start-up M&A surged, led by Vertex's acquisition of Semma. 

Financing Deals

Japan Approves Biosimilar Teriparatide And Darbepoetin

Japan’s first biosimilar teriparatide has been approved for Mochida Pharmaceutical, while competition in the darbepoetin alfa arena looks set to step up following two recent authorizations.

Biosimilars Japan

Venture Funding Deals: Korean D&D Raises $137.1m For Subsidiary Model

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in July and August.
Deals Financing

Dong-A Vows Legal Steps As Korea Imposes Heavy Penalties Over Rebates

Korea temporarily suspends reimbursement of drugs involved in Dong-A ST’s alleged illegal rebate payments to doctors, raising concerns from the industry whether the new measures are appropriate. The company concedes it violated the Pharmaceutical Affairs Act but vows to seek legal redress as it claims there are substantial issues with the punitive measures.

South Korea Reimbursement
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Gastrointestinal
  • Gynecological, Urological
  • Hepatic (Liver)
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Dong-A ST Co. Ltd.
  • Senior Management
  • Kang Su Hyeong, CEO
  • Contact Info
  • Dong-A ST Co. Ltd.
    Phone: 2-9208111
    64 Cheonho-daero
    Seoul, 02587
    South Korea
UsernamePublicRestriction

Register